System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ming-Hua Zheng is an expert in Hepatology at First Affiliated Hospital of Wenzhou Medical University (China). As of July 2026, ScienceLeadR ranks Ming-Hua Zheng in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Coronavirus Infections. Ming-Hua Zheng has authored 527 publications, the most recent in 2025, and is an investigator in 13 clinical trials, 5 of them ongoing. SLR score: 2,368 (community average: 125). How the SLR is computed.

LeadR Profile

Ming-Hua Zheng First Affiliated Hospital of Wenzhou Medical University China
2 368 ScienceLeadR Reputation 2368

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2025
Source: PubMed

First Affiliated Hospital of Wenzhou Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 527

Citations

Citations: 20 605 1st author: 42 Last author: 237 Unique author: 2

Main journals

J Hepatol 46
BMJ 21
Oncotarget 19
Liver Int 18
Aliment Pharmacol Ther 15

Best Journals

J Hepatol 23
Cell Metab 7
Lancet Gastroenterol Hepatol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Incretin-based therapies for Cardio-Kidney-Liver-Metabolic (CKLM) Disease: The role of the liver in the modern era of chronic disease management.
PMID 41146519 — liver diseases, disease management, chronic disease, kidney, liver, incretins, therapeutics		Clin Mol Hepatol20250
Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis.
PMID 40316227 — liver diseases, mortality, classification, liver		Am J Med20257
DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population.
PMID 40403723 — diabetes mellitus, fibrosis, aspartate aminotransferases, transaminases, liver, algorithms, diabetes mellitus, type 2		Med20250
Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes.
PMID 40746017 — stents, constriction, pathologic, coronary artery disease, myocardial infarction, incidence, fibrosis, percutaneous coronary intervention, arteries, liver, pharmacology, therapeutics, thrombosis		Aliment Pharmacol Ther20254
Reconsidering statins in MASLD: beyond cardiovascular protection to multisystem benefit.
PMID 40744723 — gastroenterology, hydroxymethylglutaryl-coa reductase inhibitors		Gut20250

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 2

By phase:

N/A 6
Phase 3 3
Phase 2 2
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 5
Recruiting 3
Unknown 3
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 9
Observational 4

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 2
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353 — cholangitis, ursodeoxycholic acid, safety, liver cirrhosis, liver, liver cirrhosis, biliary		Phase 3Recruiting2025
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic		Phase 3Recruiting2025
a Safety Tolerability and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease NAFLD
NCT07128797 — liver diseases, injections, safety, non-alcoholic fatty liver disease, multiple chronic conditions, liver, alcoholics, fatty liver, injections, subcutaneous, fatty liver, alcoholic, pharmacokinetics		Phase 1Recruiting2025
A Non invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B
NCT06041022 — laboratories, retrospective studies, multiple chronic conditions, biopsy, hepatitis, chronic, liver, hepatitis a, therapeutics, hepatitis b, antiviral agents, hepatitis b, chronic, hepatitis		N/ANot yet recruiting2023
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS